Abstracts Archive - Page 1967 of 2425 - ACR Meeting Abstracts

Abstract Number: 1276 • 2014 ACR/ARHP Annual Meeting
Hyperglycemia and Risk of Osteoarthritis
Mona Walimbe¹, Ann V. Schwartz², Irina Tolstykh², Charles E. McCulloch², David T. Felson³, Cora E. Lewis⁴, Neil A. Segal⁵, Michael C. Nevitt² and Nancy E. Lane⁶, ¹Medicine, UCSF (University of California, San Francisco), San Francisco, CA, ²Epidemiology & Biostatistics, UCSF (University of California, San Francisco), San Francisco, CA, ³Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA, ⁴Preventive Medicine, The University of Alabama at Birmingham, Birmingham, AL, ⁵Orthopaedics and Rehabilitation, University of Iowa, Iowa City, IA, ⁶Internal Medicine, Center for Musculoskeletal Health, UC Davis School of Medicine, Sacramento, CA
Background/Purpose Osteoarthritis (OA) is reported to be more prevalent in individuals with diabetes mellitus (DM). Potential etiologies include advanced glycation endproducts, which reduce cartilage integrity,…
Abstract Number: 1275 • 2014 ACR/ARHP Annual Meeting
Association Between Cardiometabolic Disorders and Hand Osteoarthritis Severity: A Cross-Sectional and Longitudinal Study
Alice Courties¹, Jérémie Sellam¹, Francis Berenbaum¹, Emmanuel Maheu¹, Yoann Barthe², Fabrice Carrat² and Christian Cadet³, ¹AP-HP, Saint-Antoine Hospital, Rheumatology Department and DHU i2B, Paris, France, ²Public Health, Saint-Antoine Hospital, Inserm UMRS_1136, UPMC Univ Paris 06, AP-HP, Paris, France, ³Rheumatology, Private office, Paris, France
Background/Purpose Obesity and metabolic disorders increase the risk of hand osteoarthritis (HOA). This study aimed to determine i) clinical and radiographic features associated with HOA…
Abstract Number: 1274 • 2014 ACR/ARHP Annual Meeting
Patients with Osteoarthritis Do NOT Have Increased Risk of Cardiovascular Disease in Ullensaker Community in Norway
Silvia Rollefstad¹, Ingvild Eeg², Ida K. Haugen², Inge C. Olsen³, Nina Østerås⁴, Barbara Christensen², Hilde Berner Hammer⁵, Lars Nordsletten⁶, Bård Natvig⁷, Tore K. Kvien⁸ and Anne Grete Semb¹, ¹Preventive Cardio-Rheuma clinic, Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Department of rheumatology, National Advisory Unit for rehabilitation in rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁵Postboks 23 Vinderen, Diakonhjemmet Hospital, Oslo, Norway, ⁶Dept of Orthopaedic Surgery, Oslo University Hospital, Oslo, Norway, ⁷General Practice, Oslo University, Oslo, Norway, ⁸Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose Controversies exist regarding whether patients with osteoarthritis (OA) have an increased risk of cardiovascular (CV) disease. Our aim was to evaluate the CV risk…
Abstract Number: 1273 • 2014 ACR/ARHP Annual Meeting
Assessment of the Effect of Rituximab in the Treatment of Interstitial Lung Disease associated with the Antisynthetase Syndrome
Tracy Doyle¹, Juan Osorio², Eduarda Nilo DeMagaldi³, Rachna Madan⁴, Fernanda Cabral⁵, Ivan Rosas² and Paul Dellaripa⁶, ¹Division of pulmonary medicine, Brigham and Women's Hospital, Boston, MA, ²Division of pulmonary medicine, Brigham and Women's Hospital, Boston, MA, ³medicine, Harvard Medical School, Boston, MA, ⁴Radiology, Brigham and women's Hospital, Boston, MA, ⁵Radiiology, Brigham and women's Hospital, boston, MA, ⁶Division of Rheumatology, Brigham and Women's Hospital, Boston, MA
Background/purpose: To assess clinical outcomes including pulmonary function and radiographic imaging in patients with ILD and the antisynthetase syndrome who were treated with Rituxan (RTX)Methods:…
Abstract Number: 1272 • 2014 ACR/ARHP Annual Meeting
Myositis-Specific and Myositis Associated Autoantibodies in Indian Patients with Inflammatory Myositis
Puja Srivastava, Ramnath Misra, Able Lawrence, Amita Aggarwal and Vikas Agarwal, Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
Background/Purpose Recently, idiopathic inflammatory myositis (IIM) has been categorised into distinct subsets based on myositis specific autoantibodies (MSA) and myositis associated autoantibodies (MAA). However, there is…
Abstract Number: 1271 • 2014 ACR/ARHP Annual Meeting
Myocarditis in Antisynthetase Syndrome
Céline Dieval¹, Olivier Benveniste², Christophe Deligny³, Alain Meyer⁴, Guillaume Lefevre⁵, Yoland Schoindre⁶, Aude Rigolet⁷ and Baptiste Hervier⁸, ¹Internal Medicine, Rochefort Hospital, Rochefort, France, ²UMR 974, Sorbonne Universités, University Pierre et Marie-Curie-Paris 6, INSERM, Paris, France, ³Internal Medicine, CHU Fort de France, Fort de France, France, ⁴Division of Rheumatology, University Hospital of Strasbourg, Strasbourg, France, ⁵Internal Medicine, CHRU Lille, Lille, France, ⁶DHU 2iB Internal Medicine Referal Center for Autoimmune diseases Pitie Hospital, PARIS, France, ⁷Department: inflammation, immunopathology and biotherapy (DHU i2B), Assistance Publique - Hôpitaux de Paris, Pitié-Salpêtrière University Hospital, Paris, France, ⁸Internal Medicine & Clinical Immunology Dpt, Pitié-Salpêtrière Hospital, APHP, Paris, France
Background/Purpose Antisynthetase syndrome (aSS) corresponds to an overlapping inflammatory myopathy identified by different myositis specific autoantibodies (directed against tRNA-synthetases). Myocardial involvement in this condition is poorly…
Abstract Number: 1270 • 2014 ACR/ARHP Annual Meeting
Distinctive Muscle Histopathological Features of Anti-Synthetase Syndrome
Baptiste Hervier¹, Yves Allenbach², Lenaig Mescam-Mancini³, Thierry Maisonobe⁴, Werner Stenzel⁵, Aude Rigolet⁶ and Olivier Benveniste², ¹Internal Medicine & Clinical Immunology Dpt, Pitié-Salpêtrière Hospital, APHP, Paris, France, ²UMR 974, Sorbonne Universités, University Pierre et Marie-Curie-Paris 6, INSERM, Paris, France, ³Pathology Dpt, University hospital, Grenoble, France, ⁴Neuropathology, Pitie-Salpetriere Hospital, Paris, France, ⁵Department of Neuropathology, Charite Hospital, Berlin, Germany, ⁶Department: inflammation, immunopathology and biotherapy (DHU i2B), Assistance Publique - Hôpitaux de Paris, Pitié-Salpêtrière University Hospital, Paris, France
Background/Purpose As supported by recent studies, anti-histidyl tRNA synthetase (anti-Jo1) antibodies are specific for clinico-biological features and outcomes. Though, anti-Jo1 synthetase syndrome is a clinical…
Abstract Number: 1269 • 2014 ACR/ARHP Annual Meeting
Epidemiology and Characteristics of Antisynthetase Syndrome in the African Descent Population of Martinique
Christophe Deligny¹, Maryvonne Dueymes², Serge Arfi¹, José Zécler³, Maia Forgues⁴, Véronique Dehlinger⁵, Michel DeBandt⁶, Lauren Brunier-Agot⁶, Remi Bellance⁷, Isabelle Lamaury⁸, Nadege Cordel⁸, Nicolas Baillet⁹, Gilbert. Cadelis¹⁰, Georges Jean Baptiste¹¹ and Katlyne Polomat¹², ¹Rhumatologie Et Médecine Interne, Centre hospitalier Universitaire de Fort de France, Fort de France, Martinique, ²Immunology, Centre Hospitalier Universitaire de Fort de France, Fort de France, Martinique, ³Respiratory, Centre Hospitalier Universitaire de Fort de France, Fort de France, Martinique, ⁴Internal medicine, Centre Hospitalier Andre Rosemon, Cayenne, French Guiana, ⁵Rheumatology, Centre Hospitalier universitaire de Fort de France, Fort De France - Martinique, Martinique, ⁶Rheumatology, Centre Hospitalier universitaire de Fort de France, Fort de France, Martinique, ⁷National center for rare neuromuscular disorders, Centre Hospitalier universitaire de Fort de France, Fort de France, Martinique, ⁸Infectious diseases, dermatology and internal medicine, Centre Hospitalier universitaire de Guadeloupe, Pointe à Pitre, Guadeloupe, ⁹internal medicine, Centre Hospitalier de la Basse Terre, Basse Terre, Guadeloupe, ¹⁰Respiratory, Cnetre Hospitalier Universitaire de Guadeloupe, Pointe à Pitre, Guadeloupe, ¹¹Rheumatology, Centre Hospitalier Universitaire de Fort de France, Fort de France, Guadeloupe, ¹²Centre Hospitalier universitaire de Fort de France, Fort de France, Martinique
Background/Purpose : There is no population based epidemiologic studies of antisynthetase syndrome (ASS). We described characteristics and epidemiology of this disease in Martinique, populated by…
Abstract Number: 1268 • 2014 ACR/ARHP Annual Meeting
Study of Autoantibodies in a cohort of Mexican patients with idiopathic inflammatory myopathies
Yelitza Gonzalez-Bello¹, Miguel Angel Ortiz-Villalvazo², Ignacio Garcia-Valladares¹, Gabriel Medrano-Ramírez³, José E. Navarro-Zarza⁴, Lilia Andrade-Ortega⁵, Arnulfo Nava-Zavala⁶, Gerardo Orozco-Barocio¹, Marco Maradiaga-Ceceña⁷, Marvin Fritzler⁸ and Ignacio Garcia-De La Torre⁹, ¹Immunology and Rheumatology, Hospital General de Occidente, Zapopan, Jal., Mexico, ²Internal Medicine, Hospital Civil de Guadalajara, Guadalajara, Jal., Mexico, ³Rheumatology, Hospital General de Mexico de la Secretaría de Salud, Mexico City, Mexico, ⁴Rheumatology, Hospital General de Chilpancingo, Chilpancingo, Gro., Mexico, ⁵Rheumatology, CMN 20 Noviembre ISSSTE, Mexico City, Mexico, ⁶Rheumatology, Hospital General de Occidente, Zapopan, Jal., Mexico, ⁷Rheumatology, Hospital General de Culiacan de la Secretaría de Salud, Culiacan, Sin., Mexico, ⁸Medicine, University of Calgary, Calgary, AB, Canada, ⁹Immunology and Rheumatology, Universidad de Guadalajara, Guadalajara, Jal., Mexico
Background/Purpose Idiopathic inflammatory myopathies (IIM) are a group of autoimmune disorders characterized by muscle inflammation, progressive weakness with a combination of clinical, electromyography and laboratory…
Abstract Number: 1267 • 2014 ACR/ARHP Annual Meeting
Are Anti-SRP Auto-Antibodies Specific for Myositis?
Samantha Rodriguez-Muguruza¹, Ines Lozano², Jaume Coll³, Maria Lourdes Mateo¹, Susana Holgado¹, Eva Martínez-Cácerez² and Alejandro Olivé Marqués¹, ¹Rheumatology, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, ²Immunology, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, ³Neurology, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain
Background/Purpose . Myositis-specific auto-antibodies (Ab) include those directed against aminoacyl-tRNA synthetases (ARS), signal recognition particle (SRP) and nuclear helicase Mi-2. Anti-SRP Ab are among the…
Abstract Number: 1266 • 2014 ACR/ARHP Annual Meeting
Anti-MDA5 Is Associated with Rapidly-Progressive Interstitial Lung Disease and Poor Survival in U.S. Patients with Amyopathic and Myopathic Dermatomyositis
Siamak Moghadam-Kia¹, Chester V. Oddis², Shinji Sato³, Masataka Kuwana⁴ and Rohit Aggarwal¹, ¹Medicine, University of Pittsburgh, Pittsburgh, PA, ²Rheum/Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ³Division of Rheumatology, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Japan, ⁴Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
Background/Purpose : Clinically amyopathic dermatomyositis (CADM) is a subset of dermatomyositis (DM) presenting with the characteristic rash(es) of DM without objective muscle weakness. Asian studies…
Abstract Number: 1265 • 2014 ACR/ARHP Annual Meeting
Diabetes and Atorvastatin Are Potential Risk Factors for Statin-Associated Myopathy with Autoantibodies Against 3-Hydroxy-3-Methylglutaryl-Coenzyme a Reductase
Pari Basharat¹, Arash Lahouti H.¹, Andrew L. Mammen², Iago Pinal-Fernandez¹, Tanmayee Bichile³, Thomas E. Lloyd⁴, Sonye K. Danoff⁵, Livia Casciola-Rosen⁶ and Lisa Christopher-Stine⁷, ¹Medicine, Johns Hopkins University, Baltimore, MD, ²Neurology and Medicine, Johns Hopkins University, Baltimore, MD, ³Rehumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Neurology, Johns Hopkins, Baltimore, MD, ⁵Medicine/Pulmonary, Johns Hopkins University, Baltimore, MD, ⁶Center Tower Ste 5300, Johns Hopkins University School of Medicine, Baltimore, MD, ⁷Medicine and Neurology, Johns Hopkins University, Baltimore, MD
Background/Purpose The idiopathic inflammatory myopathies (IIM) comprise a group of autoimmune disorders that target skeletal muscle. Some IIM cases may be associated with an autoantibody…
Abstract Number: 1264 • 2014 ACR/ARHP Annual Meeting
Analysis of Clinical Manifestations and Myositis-Specific Autoantibodies Associated with Severity of Physical Dysfunction after Treatment for Polymyositis and Dermatomyositis
Hidenaga Kawasumi¹, Takahisa Gono¹, Yasushi Kawaguchi¹, Yasuhiro Katsumata¹, Hisae Ichida¹, Akiko Tochimoto¹, Masanori Hanaoka¹, Yuko Okamoto¹, Sayuri Kataoka¹ and Hisashi Yamanaka², ¹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
Background/Purpose: Half of all polymyositis (PM)/dermatomyositis (DM) patients suffer from muscle weakness after initial treatment. Therefore, many patients with PM/DM have trouble with daily living…
Abstract Number: 1246 • 2014 ACR/ARHP Annual Meeting
Assessment of Protective Factors of Bone Mineral Density in a New Orleans Sarcoidosis Population
McCall Walker¹, Harmanjot K. Grewal², Adam Janot³, Mary Yu⁴, Sophia Cenac⁵, Matthew R. Lammi^6,7 and Lesley Ann Saketkoo⁸, ¹LSUHSC School of Medicine, New Orleans, LA, ²Rheumatology, Lousiana State University Health Sciences Center, New Orleans, LA, ³Department of Ophthalmology, Virginia Commonwealth University –Medical College of Virginia, Charlottesville, VA, ⁴Internal Medicine, Louisiana State University Health Sciences Center, New Orleans, LA, ⁵Scleroderma and Sarcoidosis Patient Care and Research Center, Louisiana State University Health Science Center, New Orleans, LA, ⁶Louisiana State University Health Sciences Center, Pulmonary and Critical Medicine, New Orleans, LA, ⁷Section of Pulmonary and Critical Care Medicine, LSU Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans, LA, ⁸Scleroderma and Sarcoidosis Patient Care and Research Center, Rheumatology and Pulmonary Medicine, Louisiana State University Health Sciences Center, New Orleans, LA
Background/Purpose: Sarcoidosis often involves pathological dysregulation of dependent factors of bone metabolism, e.g. calcitriol /calcium, and administration of high dose glucocorticoids (GCs) leading to low…
Abstract Number: 1245 • 2014 ACR/ARHP Annual Meeting
Long Term Outcome of Infliximab in Severe and Refractory Systemic Sarcoidosis: Report of 16 Cases
Catherine Chapelon¹, David Saadoun¹, Lucie Biard², Matthieu Resche-Rigon³, Baptiste Hervier⁴, Nathalie Costedoat-Chalumeau⁵, Aurélie Drier⁶, Jean-Marc Léger⁷ and Patrice Cacoub⁸, ¹DHU 2iB Internal Medicine Referal Center for Autoimmune diseases Pitie Hospital, Paris, France, ²Hôpital St Louis, Biostatistics, Paris, France, ³Biostatistics, Hopital Saint-Louis, Paris, France, ⁴Department: inflammation, immunopathology and biotherapy (DHU i2B), Assistance Publique - Hôpitaux de Paris, Pitié-Salpêtrière University Hospital, PARIS, France, ⁵Internal Medicine, Assistance Publique-Hôpitaux de Paris, Hopital Pitié-Salpétrière, Paris, France, ⁶Hôpital Pitié-Salpêtrière, Neuroradiology, Paris, France, ⁷Neurology, Hôpital Pitié-Salpêtrière, Neurology, Paris, France, ⁸Groupe Hospitalier Pitié Salpétrière, Service de Médecine Interne, DHU i2B, Paris, France
Background/Purpose: Infliximab (IFX) appears to be effective in refractory sarcoidosis. However, data are lacking regarding its efficacy in severe sarcoidosis (i.e. with cardiac and/or neurological…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].